KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Total Current Liabilities: 2018-2024

Historic Total Current Liabilities for Esperion Therapeutics (ESPR) over the last 7 years, with Dec 2024 value amounting to $246.2 million.

  • Esperion Therapeutics' Total Current Liabilities rose 116.45% to $359.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $359.0 million, marking a year-over-year increase of 116.45%. This contributed to the annual value of $246.2 million for FY2024, which is 57.62% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Total Current Liabilities of $246.2 million as of FY2024, which was up 57.62% from $156.2 million recorded in FY2023.
  • Esperion Therapeutics' 5-year Total Current Liabilities high stood at $246.2 million for FY2024, and its period low was $73.4 million during FY2021.
  • In the last 3 years, Esperion Therapeutics' Total Current Liabilities had a median value of $156.2 million in 2023 and averaged $164.9 million.
  • As far as peak fluctuations go, Esperion Therapeutics' Total Current Liabilities fell by 22.02% in 2021, and later spiked by 69.24% in 2023.
  • Esperion Therapeutics' Total Current Liabilities (Yearly) stood at $94.1 million in 2020, then dropped by 22.02% to $73.4 million in 2021, then grew by 25.84% to $92.3 million in 2022, then skyrocketed by 69.24% to $156.2 million in 2023, then soared by 57.62% to $246.2 million in 2024.